OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform ...

Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term ...

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings ...

Steven R. Sarkisian Jr., MD, ABO, presented data from an FDA clinical trial of a travopost intracameral implant. The iDose TR (Glaukos) is indicated for reduction of intraocular pressure (IOP) using a ...

Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a ...

Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and ...

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President ...

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...